{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T00:15:36Z","timestamp":1725840936350},"reference-count":85,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","interventional.theclinics.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Interventional Cardiology Clinics"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.iccl.2024.06.005","type":"journal-article","created":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T12:08:10Z","timestamp":1723032490000},"page":"507-516","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Antithrombotic Therapy in Acute Coronary Syndrome"],"prefix":"10.1016","volume":"13","author":[{"given":"Riccardo","family":"Rinaldi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Ruberti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Brugaletta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"21","key":"10.1016\/j.iccl.2024.06.005_bib1","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1056\/NEJMra1216063","article-title":"Mechanisms of acute coronary syndromes and their implications for therapy","volume":"368","author":"Libby","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"38","key":"10.1016\/j.iccl.2024.06.005_bib2","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC Guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.iccl.2024.06.005_bib3","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/eurheartj\/ehy394","article-title":"2018 ESC\/EACTS Guidelines on myocardial revascularization","volume":"40","author":"Neumann","year":"2019","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.iccl.2024.06.005_bib4","first-page":"E4","article-title":"2021 ACC\/AHA\/SCAI Guideline for Coronary Artery Revascularization: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Lawton","year":"2022","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.iccl.2024.06.005_bib5","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1056\/NEJMp2033115","article-title":"Conquering Atherosclerotic Cardiovascular Disease \u2014 50 Years of Progress","volume":"384","author":"Gibbons","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.iccl.2024.06.005_bib6","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.atherosclerosis.2014.01.036","article-title":"Advances in mechanisms, imaging and management of the unstable plaque","volume":"233","author":"Niccoli","year":"2014","journal-title":"Atherosclerosis"},{"issue":"37","key":"10.1016\/j.iccl.2024.06.005_bib7","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.1093\/eurheartj\/ehaa481","article-title":"Management of non-culprit coronary plaques in patients with acute coronary syndrome","volume":"41","author":"Montone","year":"2020","journal-title":"Eur Heart J"},{"issue":"9","key":"10.1016\/j.iccl.2024.06.005_bib8","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.120.009177","article-title":"Impact of Bleeding and Myocardial Infarction on Mortality in All-Comer Patients Undergoing Percutaneous Coronary Intervention","volume":"13","author":"Hara","year":"2020","journal-title":"Circ Cardiovasc Interv"},{"issue":"21","key":"10.1016\/j.iccl.2024.06.005_bib9","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1056\/NEJMoa2102137","article-title":"Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease","volume":"384","author":"Jones","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.iccl.2024.06.005_bib10","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1001\/archinte.1992.00400190018006","article-title":"A\u00a0Critical Appraisal of Ticlopidine, a New Antiplatelet Agent: Effectiveness and Clinical Indications for Prophylaxis of Atherosclerotic Events","volume":"152","author":"Haynes","year":"1992","journal-title":"Arch Intern Med"},{"issue":"5","key":"10.1016\/j.iccl.2024.06.005_bib11","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1055\/s-0037-1614133","article-title":"Identification and biological activity of the active metabolite of clopidogrel","volume":"84","author":"Savi","year":"2000","journal-title":"Thromb Haemost"},{"issue":"7","key":"10.1016\/j.iccl.2024.06.005_bib12","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.iccl.2024.06.005_bib13","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1056\/NEJMoa0909475","article-title":"Dose comparisons of clopidogrel and aspirin in acute coronary syndromes","volume":"363","author":"Mehta","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"25","key":"10.1016\/j.iccl.2024.06.005_bib14","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1161\/CIRCULATIONAHA.107.740324","volume":"116","author":"Wiviott","year":"2007","journal-title":"Circulation"},{"issue":"20","key":"10.1016\/j.iccl.2024.06.005_bib15","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"10.1016\/j.iccl.2024.06.005_bib16","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1016\/j.jacc.2007.07.058","article-title":"Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes","volume":"50","author":"Storey","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.iccl.2024.06.005_bib17","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.iccl.2024.06.005_bib18","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1586\/14779072.2013.837701","article-title":"Cangrelor: a review on pharmacology and clinical trial development","volume":"11","author":"Franchi","year":"2013","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"3","key":"10.1016\/j.iccl.2024.06.005_bib19","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1001\/jama.2011.2002","article-title":"Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial","volume":"307","author":"Angiolillo","year":"2012","journal-title":"JAMA"},{"issue":"14","key":"10.1016\/j.iccl.2024.06.005_bib20","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1056\/NEJMoa1300815","article-title":"Effect of platelet inhibition with cangrelor during PCI on ischemic events","volume":"368","author":"Bhatt","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"9148","key":"10.1016\/j.iccl.2024.06.005_bib21","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0140-6736(98)11086-3","article-title":"Platelet GPIIb-IIIa blockers","volume":"353","author":"Topol","year":"1999","journal-title":"Lancet (London, England)"},{"issue":"9247","key":"10.1016\/j.iccl.2024.06.005_bib22","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1016\/S0140-6736(00)03400-0","article-title":"Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial","volume":"356","author":"Tcheng","year":"2000","journal-title":"Lancet (London, England)"},{"issue":"9272","key":"10.1016\/j.iccl.2024.06.005_bib23","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(00)05060-1","article-title":"Effect of glycoprotein IIb\/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: The GUSTO IV-ACS randomised trial","volume":"357","author":"Simoons","year":"2001","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.iccl.2024.06.005_bib24","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1001\/jama.297.6.591","article-title":"Routine upstream initiation vs deferred selective use of glycoprotein IIb\/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial","volume":"297","author":"Stone","year":"2007","journal-title":"JAMA"},{"issue":"21","key":"10.1016\/j.iccl.2024.06.005_bib25","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1056\/NEJMoa0901316","article-title":"Early versus delayed, provisional eptifibatide in acute coronary syndromes","volume":"360","author":"Giugliano","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.iccl.2024.06.005_bib26","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1161\/01.CIR.89.1.81","article-title":"Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end points analysis from the ATACS trial. Antithrombotic Therapy in Acute Coronary Syndromes Research Group","volume":"89","author":"Cohen","year":"1994","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.iccl.2024.06.005_bib27","first-page":"45","article-title":"Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial","volume":"292","author":"Ferguson","year":"2004","journal-title":"JAMA"},{"issue":"9792","key":"10.1016\/j.iccl.2024.06.005_bib28","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S0140-6736(11)60876-3","article-title":"Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial","volume":"378","author":"Montalescot","year":"2011","journal-title":"Lancet (London, England)"},{"issue":"12","key":"10.1016\/j.iccl.2024.06.005_bib29","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1016\/j.jacc.2004.02.051","article-title":"A\u00a0dose-finding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes: The Pentasaccharide in Unstable Angina (PENTUA) study","volume":"43","author":"Simoons","year":"2004","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.iccl.2024.06.005_bib30","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1161\/01.CIR.0000158485.70761.67","article-title":"Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) Pilot Trial","volume":"111","author":"Mehta","year":"2005","journal-title":"Circulation"},{"issue":"SUPPL. 2","key":"10.1016\/j.iccl.2024.06.005_bib31","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2165\/00003088-200241002-00002","article-title":"Fondaparinux sodium mechanism of action: identification of specific binding to purified and human plasma-derived proteins","volume":"41","author":"Paolucci","year":"2002","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"10.1016\/j.iccl.2024.06.005_bib32","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1001\/jama.289.7.853","article-title":"Bivalirudin and provisional glycoprotein IIb\/IIIa blockade compared with heparin and planned glycoprotein IIb\/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial","volume":"289","author":"Lincoff","year":"2003","journal-title":"JAMA"},{"issue":"21","key":"10.1016\/j.iccl.2024.06.005_bib33","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1056\/NEJMoa062437","article-title":"Bivalirudin for patients with acute coronary syndromes","volume":"355","author":"Stone","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"16","key":"10.1016\/j.iccl.2024.06.005_bib34","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1056\/NEJMoa1908973","article-title":"Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes","volume":"381","author":"Sch\u00fcpke","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.iccl.2024.06.005_bib35","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.114.002301","article-title":"Pretreatment with antiplatelet drugs in invasively managed patients with coronary artery disease in the contemporary era: review of the evidence and practice guidelines","volume":"8","author":"Capodanno","year":"2015","journal-title":"Circ Cardiovasc Interv"},{"issue":"21","key":"10.1016\/j.iccl.2024.06.005_bib36","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1016\/j.jacc.2020.08.053","article-title":"Timing of Oral P2Y12 Inhibitor Administration in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome","volume":"76","author":"Tarantini","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.iccl.2024.06.005_bib37","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1056\/NEJMoa1407024","article-title":"Prehospital ticagrelor in ST-segment elevation myocardial infarction","volume":"371","author":"Montalescot","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"9302","key":"10.1016\/j.iccl.2024.06.005_bib38","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0140-6736(02)07442-1","article-title":"Platelet glycoprotein IIb\/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials","volume":"359","author":"Boersma","year":"2002","journal-title":"Lancet (London, England)"},{"issue":"9909","key":"10.1016\/j.iccl.2024.06.005_bib39","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1016\/S0140-6736(13)61615-3","article-title":"Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data","volume":"382","author":"Steg","year":"2013","journal-title":"Lancet (London, England)"},{"issue":"7844","key":"10.1016\/j.iccl.2024.06.005_bib40","first-page":"16","article-title":"Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis","volume":"344","author":"Silvain","year":"2012","journal-title":"BMJ"},{"issue":"10366","key":"10.1016\/j.iccl.2024.06.005_bib41","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1016\/S0140-6736(22)01999-7","article-title":"Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial","volume":"400","author":"Li","year":"2022","journal-title":"Lancet (London, England)"},{"issue":"12","key":"10.1016\/j.iccl.2024.06.005_bib42","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa1706443","article-title":"Bivalirudin versus Heparin Monotherapy in Myocardial Infarction","volume":"377","author":"Erlinge","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"13","key":"10.1016\/j.iccl.2024.06.005_bib43","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1001\/jama.295.13.joc60038","article-title":"Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial","volume":"295","author":"Yusuf","year":"2006","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.iccl.2024.06.005_bib44","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1001\/jama.2010.1320","article-title":"Low-dose vs standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux: the FUTURA\/OASIS-8 randomized trial","volume":"304","author":"Steg","year":"2010","journal-title":"JAMA"},{"issue":"14","key":"10.1016\/j.iccl.2024.06.005_bib45","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJMoa055443","article-title":"Comparison of fondaparinux and enoxaparin in acute coronary syndromes","volume":"354","author":"Yusuf","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"16","key":"10.1016\/j.iccl.2024.06.005_bib46","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","article-title":"Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation","volume":"380","author":"Lopes","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"10206","key":"10.1016\/j.iccl.2024.06.005_bib47","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/S0140-6736(19)31872-0","article-title":"Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial","volume":"394","author":"Vranckx","year":"2019","journal-title":"Lancet (London, England)"},{"issue":"46","key":"10.1016\/j.iccl.2024.06.005_bib48","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1093\/eurheartj\/ehz732","volume":"40","author":"Gargiulo","year":"2019","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.iccl.2024.06.005_bib49","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1161\/CIRCULATIONAHA.120.050438","article-title":"Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective: 2021 Update","volume":"143","author":"Angiolillo","year":"2021","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.iccl.2024.06.005_bib50","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1056\/NEJMra1607714","article-title":"Management of Antithrombotic Therapy After Acute Coronary Syndromes","volume":"384","author":"Rodriguez","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"10.1016\/j.iccl.2024.06.005_bib51","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1016\/j.jacc.2009.09.076","article-title":"A\u00a0risk score to predict bleeding in patients with acute coronary syndromes","volume":"55","author":"Mehran","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"14","key":"10.1016\/j.iccl.2024.06.005_bib52","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1161\/CIRCULATIONAHA.108.828541","article-title":"Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC\/AHA Guidelines) Bleeding Score","volume":"119","author":"Subherwal","year":"2009","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.iccl.2024.06.005_bib53","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1161\/CIRCULATIONAHA.119.040167","article-title":"Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention","volume":"140","author":"Urban","year":"2019","journal-title":"Circulation"},{"issue":"10127","key":"10.1016\/j.iccl.2024.06.005_bib54","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S0140-6736(18)30493-8","article-title":"6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial","volume":"391","author":"Hahn","year":"2018","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.iccl.2024.06.005_bib55","article-title":"Six months versus 12 months dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction (DAPT-STEMI): randomised, multicentre, non-inferiority trial","volume":"363","author":"Kedhi","year":"2018","journal-title":"BMJ"},{"issue":"11","key":"10.1016\/j.iccl.2024.06.005_bib56","doi-asserted-by":"crossref","first-page":"E990","DOI":"10.4244\/EIJ-D-19-00539","article-title":"Final results of the randomised evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with a new-generation stent (REDUCE trial)","volume":"15","author":"de Luca","year":"2019","journal-title":"EuroIntervention"},{"issue":"24","key":"10.1016\/j.iccl.2024.06.005_bib57","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1001\/jama.2019.8146","article-title":"Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention: The SMART-CHOICE Randomized Clinical Trial","volume":"321","author":"Hahn","year":"2019","journal-title":"JAMA"},{"issue":"10151","key":"10.1016\/j.iccl.2024.06.005_bib58","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S0140-6736(18)31858-0","volume":"392","author":"Vranckx","year":"2018","journal-title":"Lancet (London, England)"},{"issue":"24","key":"10.1016\/j.iccl.2024.06.005_bib59","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1001\/jama.2019.8145","article-title":"Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial","volume":"321","author":"Watanabe","year":"2019","journal-title":"JAMA"},{"issue":"21","key":"10.1016\/j.iccl.2024.06.005_bib60","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1056\/NEJMoa1908419","article-title":"Ticagrelor with or without Aspirin in High-Risk Patients after PCI","volume":"381","author":"Mehran","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"10.1016\/j.iccl.2024.06.005_bib61","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1001\/jama.2020.7580","article-title":"Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial","volume":"323","author":"Kim","year":"2020","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.iccl.2024.06.005_bib62","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1001\/jamacardio.2021.5244","article-title":"Comparison of Clopidogrel Monotherapy After 1 to 2 Months of Dual Antiplatelet Therapy With 12 Months of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome: The STOPDAPT-2 ACS Randomized Clinical Trial","volume":"7","author":"Watanabe","year":"2022","journal-title":"JAMA Cardiol"},{"issue":"18","key":"10.1016\/j.iccl.2024.06.005_bib63","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1056\/NEJMoa2108749","article-title":"Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk","volume":"385","author":"Valgimigli","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.iccl.2024.06.005_bib64","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/eurheartj\/ehaa739","volume":"42","author":"Giacoppo","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.iccl.2024.06.005_bib65","article-title":"P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials","volume":"373","author":"Valgimigli","year":"2021","journal-title":"BMJ"},{"issue":"15","key":"10.1016\/j.iccl.2024.06.005_bib66","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1161\/CIRCULATIONAHA.121.056680","article-title":"Abbreviated Antiplatelet Therapy in Patients at High Bleeding Risk With or Without Oral Anticoagulant Therapy After Coronary Stenting: An Open-Label, Randomized, Controlled Trial","volume":"144","author":"Smits","year":"2021","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.iccl.2024.06.005_bib67","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.jacc.2021.06.012","article-title":"De-Escalation of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndromes","volume":"78","author":"Shoji","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"41","key":"10.1016\/j.iccl.2024.06.005_bib68","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1093\/eurheartj\/ehx175","article-title":"Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study","volume":"38","author":"Cuisset","year":"2017","journal-title":"Eur Heart J"},{"issue":"10308","key":"10.1016\/j.iccl.2024.06.005_bib69","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/S0140-6736(21)01445-8","article-title":"Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial","volume":"398","author":"Kim","year":"2021","journal-title":"Lancet (London, England)"},{"issue":"10257","key":"10.1016\/j.iccl.2024.06.005_bib70","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S0140-6736(20)31791-8","article-title":"Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial","volume":"396","author":"Kim","year":"2020","journal-title":"Lancet (London, England)"},{"issue":"8","key":"10.1016\/j.iccl.2024.06.005_bib71","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1080\/17512433.2021.1927709","article-title":"Genetic testing in patients undergoing percutaneous coronary intervention: rationale, evidence and practical recommendations","volume":"14","author":"Galli","year":"2021","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"16","key":"10.1016\/j.iccl.2024.06.005_bib72","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.jcin.2019.03.034","article-title":"Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention","volume":"12","author":"Sibbing","year":"2019","journal-title":"JACC Cardiovasc Interv"},{"issue":"10104","key":"10.1016\/j.iccl.2024.06.005_bib73","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/S0140-6736(17)32155-4","article-title":"Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial","volume":"390","author":"Sibbing","year":"2017","journal-title":"Lancet (London, England)"},{"issue":"17","key":"10.1016\/j.iccl.2024.06.005_bib74","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1907096","article-title":"A\u00a0Genotype-Guided Strategy for Oral P2Y12 Inhibitors in Primary PCI","volume":"381","author":"Claassens","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"10283","key":"10.1016\/j.iccl.2024.06.005_bib75","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/S0140-6736(21)00533-X","article-title":"Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis","volume":"397","author":"Galli","year":"2021","journal-title":"Lancet (London, England)"},{"issue":"10","key":"10.1016\/j.iccl.2024.06.005_bib76","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1093\/eurheartj\/ehab836","article-title":"Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials","volume":"43","author":"Galli","year":"2022","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.iccl.2024.06.005_bib77","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jcin.2020.01.226","article-title":"Derivation, Validation, and Prognostic Utility of a Prediction Rule for Nonresponse to Clopidogrel: The ABCD-GENE Score","volume":"13","author":"Angiolillo","year":"2020","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.iccl.2024.06.005_bib78","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ahj.2016.10.006","volume":"183","author":"Zettler","year":"2017","journal-title":"Am Heart J"},{"issue":"20","key":"10.1016\/j.iccl.2024.06.005_bib79","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1161\/CIRCULATIONAHA.117.031164","article-title":"International Expert Consensus on Switching Platelet P2Y12 Receptor-Inhibiting Therapies","volume":"136","author":"Angiolillo","year":"2017","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.iccl.2024.06.005_bib80","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.iccl.2024.06.005_bib81","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1105819","article-title":"Apixaban with antiplatelet therapy after acute coronary syndrome","volume":"365","author":"Alexander","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"10117","key":"10.1016\/j.iccl.2024.06.005_bib82","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0140-6736(17)32458-3","article-title":"Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial","volume":"391","author":"Connolly","year":"2018","journal-title":"Lancet (London, England)"},{"issue":"23","key":"10.1016\/j.iccl.2024.06.005_bib83","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","article-title":"Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents","volume":"371","author":"Mauri","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"14","key":"10.1016\/j.iccl.2024.06.005_bib84","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1093\/eurheartj\/ehv531","article-title":"Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54","volume":"37","author":"Bonaca","year":"2016","journal-title":"Eur Heart J"},{"issue":"10293","key":"10.1016\/j.iccl.2024.06.005_bib85","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1016\/S0140-6736(21)01063-1","article-title":"Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial","volume":"397","author":"Koo","year":"2021","journal-title":"Lancet (London, England)"}],"container-title":["Interventional Cardiology Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211745824000646?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211745824000646?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,8]],"date-time":"2024-09-08T22:55:53Z","timestamp":1725836153000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211745824000646"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":85,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S2211745824000646"],"URL":"https:\/\/doi.org\/10.1016\/j.iccl.2024.06.005","relation":{},"ISSN":["2211-7458"],"issn-type":[{"type":"print","value":"2211-7458"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antithrombotic Therapy in Acute Coronary Syndrome","name":"articletitle","label":"Article Title"},{"value":"Interventional Cardiology Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.iccl.2024.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}